[1]
|
Deroo, B. J. and Korach, K. S., (2006) Estrogen receptors and human disease, J. Clin. Invest. Ann. Arbor., 116, 561–570.
|
[2]
|
Ring, A., and Dowsett, M., (2004) Mechanisms of tamoxifen resistance, Endocr-relat cancer, Bristol., 11, 643–658.
|
[3]
|
Wang, D. Z., Li, S., Hockemeyer, D., Sutherland, L., Wang, Z., Schratt, G., et al, (2002) Potentiation of serum response factor activity by a family of myocardin-related transcription factors, Proc. Natl. Acad. Sci., USA, Washington, 99, 14855–14860.
|
[4]
|
Teg Pipes, G. C., Creemers, E. E., and Olson, E. N., (2006) The myocardin family of transcriptional coactivators: Versatile regulators of cell growth, migration, and myogenesis, Gene dev, Cold Spring Harbor, 20, 1545– 1556.
|
[5]
|
Sun, Y., Boyd, K., Xu, W., Ma, J., Jackson, C. W., Fu, A., et al, (2006) Acute myeloid leukemia-associated mkl1 (mrtf-a) is a key regulator of mammary gland function, Mol. Cell Biol., Washington, 26, 5809–5826.
|
[6]
|
Li, S., Chang, S., Qi, X., Richardson, J. A., and Olson, E. N., (2006) Requirement of a myocardin-ralated transcription factor for development of mammary myoepithelial cells, Mol. Cell Biol., Washington, 26, 5797–5808.
|
[7]
|
Sun, Q., Chen, G., Streb, J. W., Long, X., Yang, Y., Stoeckert, C. J., et al, (2006) Defining the mammalian CarGome, Genome. Res., Cold Spring Harbor, 16, 197– 207.
|
[8]
|
Jordan, V. C., (2003) Is tamoxifen the rosetta stone for breast cancer, J. Natl. Cancer. Inst. Bethesda, 95, 338– 340.
|
[9]
|
Hilsenbeck, S. G., Friedrichs, W. E., Schiff, R., O’Connell, P., Hansen, R. K., Osborne, C. K., et al, (1999) Statistical analysis of array expression data as applied to the problem of tamoxifen resistance, J. Natl. Cancer. Inst. Bethesda, 91, 453–459.
|
[10]
|
Mannisto, P. T. and Kaakkola, S., (2008) Catechol-O- methyl-transferase (COMT): Biochemistry, molecular biology, phar-macology, and clinical efficacy of the new selective COMT inhibitors, Pharmacol. rev. Bethesda, 51, 593–628.
|
[11]
|
Singh, M. N., Stringfellow, H. E., Walsh, M. J., Ashton, K. M., Paraskevaidis, E., Abdo, K. R., et al, (2008) Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in hu-man endometrium, Toxicology, Limerick, 249, 85–90.
|
[12]
|
Dehal, S. S. and Kupfer, D., (1995) Evidence that the catechol 3, 4-dihydroxytamosifen is a proximate intermediate to the reactive species binding covalently to proteins, Cancer Res. Baltimore, 56, 1283–1290.
|
[13]
|
Cen, B., Selvaraj, A., Burgess, R. C., Hitzler, J. K., Ma, Z., Morris, S. W., et al, (2003) Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes, Mol Cell Biol., Washington, 23, 6597– 6606.
|
[14]
|
Dubey, R. K., Gillespie, D. G., Zacharia, L. C., Barchiesi, F., Imthurn, B., and Jackson, E. K., (2003) CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs, Hypertension, Dallas, 41, 807–813.
|
[15]
|
Dubey, R. K., Tofovic, S. P., and Jackson, E. K., (2004) Car-diovascular pharmacology of estradiol metabolites, J. Pharma-col. Exp. Ther., Bethesda, 308, 403–409.
|
[16]
|
Wentz, M. J., Jamaluddin, M., Garfield, R. E., Al-Hendy, A., (2006) Regulation of catechol-O-methyltransferase expression in human myometrial cells, Obstet. Gynecol., Hagerstown, 108, 1439–1447.
|